Dr. Sikorski is an independent drug developer and Managing Director of Woodside Way Ventures. He is also the founding CMO of Indapta Therapeutics, a biotech company developing NK cell therapies. Dr. Sikorski currently focuses on advancing next-generation therapies for serious diseases. Previously, as the Chief Medical Officer of FivePrime Therapeutics, he built a development organization, led clinical programs that advanced oncology drugs to Phase III, and led a steering committee managing a $350 million partnership agreement before the company was acquired by Amgen for $1.9 billion. As a Senior Director of Global Oncology Research and Development at MedImmune, he managed an early development portfolio of ten cancer therapeutics. Here, he led the initial development of tremelimumab (anti-CTLA4) and oleclumab (anti-CD73) with both drugs now in Phase III trials in lung cancer. As a Director of Global Oncology Research and Development at Amgen, he was instrumental in advancing a successful pivotal Phase III trial for Vectibix that gained European Marketing Authorization based on the first gene mutation companion diagnostic in colorectal cancer. He has been board-certified in both oncology and internal medicine and has served as an editor for Science magazine and the Journal of the American Medical Association.